A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects with Nonalcoholic Steatohepatitis and Fibrosis
Primary Objective
To evaluate the effect of Saroglitazar Magnesium (2 mg and 4 mg) compared with Placebo on resolution of steatohepatitis on overall histopathological reading and no worsening of liver fibrosis at Week 76/EOT.
Details
Age
Adult
Type of Study
Treatment
Scope
National
Locations
University of Colorado Hospital
Principal Investigator
Amanda Wieland, MD
Study ID
Protocol Number: 21-3466
More information available at ClinicalTrials.gov: NCT05011305
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers